Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376991 | 0.89 | POLB (0.46) | GPR119MAPTACACBACACAKDM4E | |
| SCHEMBL376500 | 0.88 | MAPT (0.46) | GPR119MAPTKDM1AMEN1KMT2A | |
| SCHEMBL376786 | 0.88 | KDM1A (0.45) | GPR119KDM1AHRH3MEN1KMT2A | |
| SCHEMBL8111261 | 0.88 | GPR119 (0.49) | GPR119MAPTSMN1; SMN2KDM1AKDM1B | |
| SCHEMBL4818025 | 0.86 | STS (0.47) | GPR119SMN1; SMN2HRH3ACACBACACA | |
| SCHEMBL376318 | 0.78 | SLC6A4 (0.39) | SMN1; SMN2KMT2ADPP4 | |
| SCHEMBL8116325 | 0.77 | GPR119 (0.51) | GPR119MAPTSMN1; SMN2KDM1AKDM1B | |
| SCHEMBL376371 | 0.76 | MAPT (0.43) | MAPTHRH3MEN1KMT2AKDM4E | |
| SCHEMBL376372 | 0.76 | MAPT (0.43) | MAPTHRH3MEN1KMT2AKDM4E | |
| SCHEMBL2469956 | 0.75 | GPR119 (0.49) | GPR119MAPTSMN1; SMN2KDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | GPR119 1298/4885MAPT 4433/4885SMN1; SMN2 808/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | GPR119 1298/4885MAPT 4433/4885SMN1; SMN2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.